Comment
doi: 10.1016/j.annonc.2021.05.794.
Epub 2021 May 21.
Association between HER2 status in residual disease and sensitivity to trastuzumab emtansine
Affiliations
- PMID: 34023398
- DOI: 10.1016/j.annonc.2021.05.794
Item in Clipboard
Comment
Association between HER2 status in residual disease and sensitivity to trastuzumab emtansine
Ann Oncol.
2021 Sep.
Free article
No abstract available
Conflict of interest statement
Disclosure The author has declared no conflicts of interest.
Comment in
-
Characteristics of residual invasive breast cancer after neoadjuvant therapy in the KATHERINE study.Ann Oncol. 2021 Sep;32(9):1191-1192. doi: 10.1016/j.annonc.2021.05.802. Epub 2021 May 29. Ann Oncol. 2021. PMID: 34058348 No abstract available.
Comment on
-
Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE.Ann Oncol. 2021 Aug;32(8):1005-1014. doi: 10.1016/j.annonc.2021.04.011. Epub 2021 Apr 28. Ann Oncol. 2021. PMID: 33932503 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
